Clopidogrel is a prodrug that is used to treat blood clots. The irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets suppresses platelet activation and aggregation. Platelet aggregation inhibition is dose-dependent and visible 2 hours after single oral dosages. On the first day, repeated 75 mg doses decrease ADP-induced platelet aggregation, and inhibition achieves a stable state between Days 3 and 7.
Syndrome: In patients who need an antiplatelet effect within
hours, initiate clopidogrel with a single 300 mg (4 tablets) oral loading dose
and then continue at 75 mg once daily. Initiating it without a loading dose
will delay the establishment of an antiplatelet effect by several days.
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: 75 mg once daily orally without a loading dose.
It is given orally with or without food.
NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): CYP2C19 inhibitors (omeprazole or esomeprazole): Increases the risk of bleeding. Avoid taking omeprazole or esomeprazole at the same time.
Repaglinide (substrates for CYP2C8): Clopidogrel should not be taken with Repaglinide since it raises Repaglinide plasma level.
Livocard should not be used if you have any of the following conditions: Hypersensitivity to the medicine or any of the product's components. Peptic ulcer or cerebral hemorrhage are examples of active pathological bleeding.
Livocard is a medication that is generally well
Bleeding, diarrhea, gastrointestinal discomfort, hemorrhage, and skin responses are all common adverse effects. Acquired hemophilia, anemia, angioedema, arthralgia, arthritis, and bone marrow abnormalities are all rare adverse effects.
In pregnant women, there are no sufficient and well-controlled trials. It should only be used during pregnancy if absolutely necessary. Livocard is not known to be excreted in human breast milk. Considering the medicine's value to the mother, a decision should be taken whether to quit nursing or discontinue the drug.
Livocard should not be used if you have any of the following conditions: Because tA is a prodrug, genetic polymorphisms in CYP2C19 (a poor metabolizer) and medicines that inhibit CYP2C19, such as Omeprazole and Esomeprazole, hinder metabolism to its active metabolite. Clopidogrel's antiplatelet action may be reduced if it is taken with certain medications or if you have a CYP2C19 poor metaboliser.
The risk of bleeding may increase since it inhibits platelet aggregation during the platelet's whole lifetime (7-10 days). Platelet transfusions given within 4 hours of the loading dosage or 2 hours of the maintenance dose may be less efficient in restoring hemostasis.
The risk of bleeding increases if you stop using Clopidogrel.
Do not store at temperatures above 30°C. Keep out of children's reach.